Introdoction:The concept of prebiotics was first introduced by Glenn Gibson and Marcel Roberfreud in June 1995. prebiotics include non-digestible food substances that help improve the health of the host by stimulating the growth and activity of specific bacteria in the large intestine. Colorectal cancer (CRC) is a significant global health concern, necessitating innovative strategies for prevention and treatment. This contemporary review examines the role of prebiotics in CRC management, focusing on their potential to modulate gut microbiota, enhance immune responses, and reduce inflammation. Prebiotics, dietary fibers that promote the growth of beneficial gut bacteria, may play a crucial role in maintaining gut health and preventing tumorigenesis.

Methods: We analyze recent studies that highlight the mechanisms by which prebiotics exert their effects, including the production of short-chain fatty acids (SCFAs) and their impact on cellular signaling pathways. Additionally, we explore the synergistic potential of prebiotics when combined with conventional therapies, assessing their role in improving treatment outcomes and mitigating side effects.

Results: This review aims to provide a comprehensive understanding of the current evidence regarding prebiotics in the context of colorectal cancer, emphasizing their potential as a complementary approach in CRC prevention and therapy.

Conclusion: Future research directions are suggested to further elucidate the clinical applications of prebiotics in CRC management.